MUSTT

MUSTT

Abbreviation for:
Multicentre Unsustained Tachycardia Trial

MUSTT

Cardiology
1. A clinical study–Multicenter Unstable Tachycardia Trial.
2. A clinical study–Multicenter Unsustained Tachycardia Trial. See Calgary-MUSTT.
Mentioned in ?
References in periodicals archive ?
This measure has dramatically increased accuracy and accountability in tracking motorcycle riders across the wing and in MUSTT.
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.
The average age of the patients enrolled in several of the major ICD trials, such as the Multicenter Automatic Defibrillator Implantation Trial (MADIT), MUSTT, and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), was 60-67 years.
35 MUSTT (1999) (22) 704 patients with ischemic Inducible, sustained cardiomyopathy and LVEF ventricular [less than or equal to] tachyarrhythmias 0.
Previous trials, including MADIT, MUSTT and AVID, have demonstrated that implantable defibrillators improve survival in other patient populations.
It's the MUSTT System in action and nobody has improved on it.
Based on the results of both the Antiarrhythmics Versus Implantable Defibrillators [AVID] Registry and MUSTT [the Multicenter Unsustained Tachycardia Trial], [ldots] we should be very actively searching in our practices for these patients.
In addition to COMPANION, MADIT II and MUSTT, other Guidant solely or jointly sponsored trials include MADIT, CONTAK CD(R) and AVID.
Earlier trials such as MADIT and MUSTT have demonstrated a significant impact on clinical practice around the world.
The DEBUT trial builds on the results of other landmark studies, such as MADIT, AVID, and MUSTT, that demonstrate the lifesaving value of implantable defibrillation therapy," said Fred McCoy, president, cardiac rhythm management, Guidant Corporation.
Recent data from the MUSTT trial and elsewhere has given electrophysiologists (EP's) concern about the predictive accuracy of EP testing in many situations.
The results of the MUSTT trial, published today in the New England Journal of Medicine, showed a 74 percent reduction in sudden cardiac death for certain patients with coronary heart disease who received an implantable cardioverter defibrillator (ICD).